Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958698 | 0.89 | CA1 (0.45) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL3902529 | 0.87 | CA1 (0.44) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL17843471 | 0.86 | MMP2 (0.39) | CA1CA2CA4CA9HTR6 | |
| SCHEMBL30872532 | 0.86 | HTR6 (0.41) | CA1CA2CA4CA9HTR6 | |
| SCHEMBL2253695 | 0.82 | NR1H2 (0.44) | CA1CA2CA4CA9 | |
| SCHEMBL30407459 | 0.79 | CHRM2 (0.43) | HTR6CHRM2CHRM1KAT6AALDH1A1 | |
| SCHEMBL28061774 | 0.79 | HTR6 (0.42) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL29060773 | 0.78 | CA1 (0.38) | CA1CA2CA4CA9CHRM2 | |
| SCHEMBL3796418 | 0.78 | SLC6A2 (0.49) | SIGMAR1HTR6CHRM2CHRM1KAT6A | |
| Fluoride SCHEMBL28061775 | 0.78 | HTR6 (0.41) | CA1CA2CA4CA9SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | claimed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | claimed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| EP-3027593-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017393-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC | 2004-03-25 | — | — | US | disclosed |
| US-6696418-B1 | ANIMAL GROWTH REGULATORS SUCH AS 6-AMINO-2-(2-((1-BENZENE SULFONYL-PIPERIDINE-4-CARBONYL)-AMINO)-3-(1H-INDOL-3-YL)-PROPIONYLAMINO) -HEXANOIC ACID TERT-BUTYL ESTER, ADMINISTERED TO MODULATE CELL DIFFERENTIATION | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | HAY BRUCE A (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| EP-1086947-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128206-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | CA1 1137/4885CA2 514/4885CA4 1131/4885 |
| US-20020016298-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | CA1 1154/4885CA2 521/4885CA4 1114/4885 |
| US-20040058877-A1 | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | GHSR, SSTR1, GHRHR | CA1 1154/4885CA2 521/4885CA4 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.